Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Receivables (2019 - 2025)

Voyager Therapeutics' Change in Receivables history spans 4 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 90.14% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached $257000.0, up 100.33%, while the annual FY2025 figure was $257000.0, 100.33% up from the prior year.
  • Change in Receivables for Q4 2025 was -$1.4 million at Voyager Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $25.0 million in Q1 2023 and bottomed at -$79.3 million in Q1 2024.
  • The 3-year median for Change in Receivables is $119000.0 (2025), against an average of -$5.9 million.
  • The largest annual shift saw Change in Receivables tumbled 417.25% in 2024 before it skyrocketed 100.15% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $25.0 million in 2023, then tumbled by 157.8% to -$14.4 million in 2024, then surged by 90.14% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Change in Receivables are -$1.4 million (Q4 2025), $1.5 million (Q3 2025), and $51000.0 (Q2 2025).